BioSpace News Archive

LenioBio GmbH, today announced a strengthening of its Scientific Advisory Board with the appointment of Prof. Daniel Bracewell, Professor of Bioprocess Analysis at University College London’s Department of Biological Engineering.

PixCell Medical, innovator of rapid hematology testing solutions at the point-of-care, today announced a partnership with Insight Medical, a medical supply and service company based in Port Moresby, Papua New Guinea.

CurveBeam, LLC of Hatfield PA, USA and StraxCorp Pty Ltd of Melbourne VIC, Australia announced they have entered into a definitive merger agreement to form CurveBeam AI Limited. CurveBeam AI expands CurveBeam’s financially viable point-of-care imaging solutions into the bone health space, as well as springboards artificial intelligence (AI) driven applications for weight bearing CT (WBCT) imaging.

Aethlon Medical, Inc., a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, announced that it will be presenting at two investor conferences in September.

Think Bioscience (“Think”), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target difficult-to-drug proteins, has appointed Nicholas A. Saccomano, Ph.D., to its Board of Directors.

AtriCure, Inc. announced that the company will host an investor education webcast at 2:00 p.m. Eastern Time on Wednesday, September 28, 2022, focusing on Hybrid AF Therapy.

Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present interim clinical data from its ongoing TACTIC-2 clinical trial (NCT04727151) for TAC01-HER2 in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress.

ReCode Therapeutics, announced today that Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics, will present a corporate overview at 8:00 a.m. ET on Tuesday, September 13th at the upcoming Morgan Stanley 20th Annual Global Healthcare Conference being held in New York, NY.

Daiichi Sankyo (TSE: 4568) continues to make bold strides in oncology with the presentation of new clinical research across its innovative DXd antibody drug conjugate (ADC) portfolio in a broad range of cancers including lung, breast, gastric, esophageal and prostate at the 2022 European Society for Medical Oncology (#ESMO22) Congress to be held September 9 to 13, 2022.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience will present at the Baird 2022 Global Healthcare Conference.